Kornimate/medical-research-clean huggingface dataset:
health economic evaluation of primovist-enhanced liver mri

Conditions: Colorectal Neoplasms; Neoplasm Metastasis

Summary: patients with a history of colorectal cancer and known or suspected liver metastases who are scheduled for contrast-enhanced tomographic imaging will be included in this study. after randomization to either primovist-enhanced mri, extracellular contrast media (eccm)-enhanced mri or contrast-enhanced (ce)-ct outcomes and resource needs of the diagnostic work-up and treatment will be evaluated for each of the three imaging modalities. main objectives of the study are to assess the proportion of patients for whom further imaging is required to come to a therapy decision and to evaluate the proportion of patients with intraoperatively modified surgical plans after primovist-enhanced mri as compared to eccm-enhanced mri and ce-ct.


Eligibility criteria:
inclusion criteria: * patients with known or suspected metachronous liver metastases secondary to colorectal cancer who are scheduled for further contrast-enhanced tomographic imaging exclusion criteria: * patients (men or women) under 18 years of age * patients who have received any contrast material within 24 hours before injection of study drug, or who are scheduled to receive any contrast material within 24 hours after injection * patients not eligible to contrast media (cm) injection according to product labeling * women who are pregnant, lactating or who are of childbearing potential and have not had a negative urine pregnancy test at baseline visit(s) * patients scheduled for liver-specific mri other than primovist-enhanced mri, i.e. multihance-, teslascan- or spio-enhanced mri * patients who are clinically unstable and whose clinical course is unpredictable (e.g. due to previous surgery, acute myocardial infarction) * patients with known anaphylactoid or anaphylactic reaction to any contrast media or hypersensitivity to any allergen including drugs * patients with a contraindication for mri or ct. * patients with severe renal impairment (egfr \< 30ml/min/1.73m2) or patients on dialysis

Keywords: gadolinium ethoxybenzyl dtpa contrast media outcome assessment (health care) magnetic resonance imaging tomography, x-ray computed liver
rituximab+standard chop vs rituximab+bi-weekly chop for untreated stage iii/iv low-grade b-cell lymphoma (jcog0203)

Conditions: Lymphoma, B-Cell

Summary: to establish standard therapy for patients with advanced-stage low grade b-cell lymphoma

since currently there is no standard therapy for untreated advanced-stage low-grade b-cell lymphoma, phase 2/3 study was planned. comparison(s): an intensified bi-weekly version by shortening the intervals of both rituximab and chop therapies using g-csf, compared to the tri-weekly r-chop regimen.

Eligibility criteria:
inclusion criteria: 1. histological confirmed, low-grade b-cell lymphoma except mantle cell lymphoma and histologic transformation to dlbcl 2. cd20-positive 3. ann arbor cs iii or iv 4. lymphoma cell count in pb≦10,000/mm3 5. 20\<=age\<=69 6. ecog ps 0-2 7. bidimensionally measurable disease \>1.5cm in a single dimension by ct scans 8. no prior chemotherapy, radiotherapy, interferon-alfa, or antibody therapy 9. normal bm, hepatic, renal, cardiac, and pulmonary function 10. written informed consent exclusion criteria: 1. cns involvement 2. glaucoma 3. dm treated by insulin 4. uncontrollable ht 5. ap, ami 6. positive hbs antigen 7. seropositive to hcv 8. seropositive to hiv 9. interstitial pneumonitis, pulmonary fibrosis, or emphysema 10. severe infection 11. liver cirrhosis 12. double cancer 13. pregnant or lactating 14. patients who desire auto pbst after cr 15. patients treated with major tranquilizer or antidepressant

Keywords: rituximab chop bi-weekly low-grade b-cell lymphoma advanced stage follicular lymphoma g-csf untreated stage iii/iv low-grade b-cell lymphoma
the effect of psoriatic arthritis on female sexual dysfunction

Conditions: Psoriatic Arthritis

Summary: psoriasis is one of the most common immunemediated chronic inflammatory skin disorders.

psoriasis is one of the most common immunemediated chronic inflammatory skin disorders. beside genetic factors, several environmental factors such as injuries, infections, stress, drugs, and immune defect take part in autoimmune pathogenesis of the disease. in addition, it has been reported that some hormones may also have a role in the pathogenesis of psoriasis, due to their effects on keratinocytes proliferation. studies revealed that sex hormones manifest a variety of biological and immunological effects in the skin which modulate the natural course of psoriasis. approximately 20-30% of patients with psoriasis may also have psoriatic arthritis, which often causes significant musculoskeletal pain that significantly impairs quality of life (qol). although sexual dysfunction is a common complaint, affecting 30 to 70% of psoriasis patients, few studies have analyzed the impact of psoriasis and psoriatic arthritis on quality of sexual life.

Eligibility criteria:
inclusion criteria: * the study will focuses on the relationship between the fsd and psa; * the healthy controls will derive from a population within the same geographic area and ethnic background as psa; * used the same questionnaires/instruments of fsfi to diagnose fsd exclusion criteria: * pregnancy, * breastfeeding * being sexually inactive * having a partner with sexual dysfunction, * refusing to participate, or * being unable to read * females with any sexual transmitted disease
diagnostic and therapeutic approaches to hyperinflation and small airway disease in copd

Conditions: COPD

Summary: current guideline-based criteria defining copd do not meet the challenges set by the complex pathophysiology of the disease. hyperinflation and affection of the small airways are two components that are not represented in current diagnostic concepts and may relate to early stages of the disease. moreover, optimal therapeutic interventions in patients with these distinct features remain unclear. the investigators therefore aimed to evaluate novel or not widely used diagnostic approaches for the detection and initiating therapeutic strategies in early stage copd within the gold recommendations.


Eligibility criteria:
inclusion criteria: * known or first diagnosis of copd * lung function testing consistent with hyperinflation or peripheral obstruction * emphysema in imaging * symptoms (dyspnea, cough, sputum) and risk factors (\>= 10 pack years) * indication for bronchodilator therapy exclusion criteria: * gold stages 3 and 4 (spirometric) * indication for dual bronchodilator therapy, triple therapy or inhaled steroid * contraindication for cardiopulmonary exercise testing * unwilling to participate

Keywords: pulmonary care copd small airway disease hyperinflation
value of oesophagal videocapsul and oeso-gastro-duodenal fiber endoscopy for the screening of oesophagal varix for cirrhotic patients

Conditions: Cirrhotic Patient With Suspicion of Portal Hypertension and in a OV Screening Context

Summary: the purpose of this study is to determine the equivalence or not of diagnosis ability of oesophagal videocapsul versus oeso-gastro-duodenal fiber endoscopy in the screening of oesophagal varix.


Eligibility criteria:
inclusion criteria: * 18\< age\< 80 * diagnosis of a cirrhosis * suspicion of portal hypertension without known diagnosis of a cirrhosis * able to give an inform consent exclusion criteria: related to pouplation * case history of cancer or oesophagal surgery * case history of an orl cancer * case history of evolutive cancer related to pathology * previous fiberoptic endoscopy with ov diagnosis * less than 6 month since last fiberoptic endoscopy related to tested device * clinical suspicion of oesophagal stenosis for a patient presenting a dysphagia to solids * zenker diverticuls attested * clinical suspicion of small intestinal stenosis * patient with pace-maker or any other inter device * pregnant women * deglutition troubles withfalse passage and/or conscience troubles
a retrospective study to characterize participants with propionic acidemia and methylmalonic acidemia

Conditions: Propionic Acidemia; Methylmalonic Acidemia

Summary: this is a non-interventional, global, multicenter, retrospective cohort study describing participant characteristics, clinical outcomes, and event rates in participants with propionic acidemia (pa) or methylmalonic acidemia (mma).

this study will abstract participants data from their medical records from approximately 2015-2025. all data will be abstracted retrospectively in 6-month increments.

Eligibility criteria:
abstraction criteria: participants' medical records are eligible for abstraction only if all of the following criteria apply: * availability of evidence supportive of the participant having received a physician's diagnosis of pa or mma due to mut deficiency as indicated by documented evidence. * participant provided informed consent (and assent, as applicable). * participant has had at least one mde in 2015 or later before eligibility assessment. censoring criteria: participants medical records meeting the following censoring criterion will not be abstracted: * participation in a clinical study of mrna-3927, mrna-3705, or another investigational agent. * other reasons of censorship of data include: * withdrawal of consent * death * lost to follow-up * end of study period
to demonstrate the relative bioavailability study of ramipril 10 mg capsules under non-fasting conditions

Conditions: Hypertension

Summary: to demonstrate the relative bioavailability study of ramipril 10 mg capsules under non-fasting conditions.


Eligibility criteria:
inclusion criteria: * no clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. exclusion criteria: * positive test results for hiv or hepatitis b or c. * treatment for drug or alcohol dependence.
efficacy of clinical pilates exercises i̇n desk-based workers with sagital cervical disorientation

Conditions: Sagital Cervical Disorientation

Summary: the aim of this study is to compare the effects of clinical pilates exercises and home exercise program on postural disorders, pain intensity, normal range of motion, muscle strength, endurance, muscle shortness, joint position sense and functional status in desk workers with sagittal cervical disorientation.


Eligibility criteria:
inclusion criteria: * neck pain at least for three months, * anterior head translation of sagittal segmental alignment disorders, * craniovertebral angle as \<50 degree, * desk-work minimum for 3 years, * working with the computer daily at least for 5 hours, * less severe physical activity level according to the international physical activity questionnaire. exclusion criteria: * taken any physiotherapy program for the last 6 months due to neck or back pain complain, * pain severe 3 cm or less according to the visual analog scale (vas), * structural scoliosis, * broken neck history * rheumatic disorder that affects the neck, * acute torticollis, * vertebral column surgical history, * spinal cord compression due to tumor or other reasons, * neurological deficit, * temporomandibular joint problem, * taking any kind of pain killers except for basic analgesics.

Keywords: clinical pilates exercise sagital cervical disorientation disorientation forward head posture
impact of probiotics on children with adhd

Conditions: Attention Deficit Hyperactivity Disorder

Summary: this study investigates wecprob (bifidobacterium animalis subsp. lactis and lacticaseibacillus rhamnosus) to evaluate their potential to improve symptoms and safety in children with adhd.


Eligibility criteria:
inclusion criteria: 1. diagnosis of adhd per dsm-5 criteria; 2. age 6-12 years, gender-neutral; 3. iq \>70 on intelligence testing; 4. participant/guardian comprehension and voluntary consent. exclusion criteria: 1. those with a clear history of other serious neurological diseases, such as epilepsy, head trauma, encephalitis or meningitis, etc.; 2. have taken antibiotics, probiotics or immunosuppressants within one month before starting the experiment; 3. ongoing special diet, such as ketogenic diet, etc 4. bmi higher than the 90th percentile or lower than the 10th percentile for children of the same age and sex; 5. those who have had symptoms of respiratory or digestive tract infection in the past month, such as fever, cough, diarrhea, etc.; 6. those who have had inflammatory bowel disease in the past, such as ulcerative colitis, crohn's disease, etc.;
effects of dry needling on mobility among children with cerebral palsy

Conditions: Cerebral Palsy (CP); Spasticity; Range of Motion; Functional Mobility

Summary: this study explores the potential of dry needling as a treatment for spasticity in the foot among children with cerebral palsy (cp). dry needling involves inserting fine needles into specific trigger points or tight muscles without injecting any substances, aiming to relieve pain, improve muscle function, and promote tissue healing. in cp-related foot spasticity, dry needling may target hypertonic muscles, inducing a local twitch response that helps release muscle tension, reduce spasticity, and enhance overall muscle function. the technique may also stimulate sensory nerves and trigger the release of endorphins, contributing to pain relief and muscle relaxation. while dry needling has shown effectiveness in reducing spasticity and improving muscle function in adults with conditions such as post-stroke, there is limited research on its benefits for children with cp. this randomized controlled trial aims to address this gap by evaluating the impact of dry needling on spasticity, range of motion, and functional mobility in children with cp.

the study will be conducted at bliss center of care and therapy in faisalabad, involving 38 participants aged 6 to 12 years, all diagnosed with spastic cerebral palsy and classified under the gross motor function classification system (gmfcs) levels i-ii. participants will be divided into two groups: an experimental group receiving dry needling therapy (dnt) and routine physical therapy (rpt) and a control group receiving rpt only. critical exclusion criteria include recent interventions, bleeding disorders, fixed joint deformities, recent seizures, botulinum toxin injections, or contraindications to dry needling. outcomes will be measured using the wartenberg pendulum test, active and passive ankle dorsiflexion range of motion, and the timed up and go test, which will be assessed before and after a 10-week intervention. data will be analyzed using spss version 23.0 to determine the efficacy of dry needling in managing spasticity in children with cp.

Eligibility criteria:
inclusion criteria: * age: 6 to 12 years old * walking ability at gross motor function classification system levels i to ii * modified modified ashworth scale (mas) score higher than equal to 1 (score up to 2) * ability to understand and execute orders * no ongoing rehabilitation intervention exclusion criteria: * recent introduction of a new intervention in addition to previous treatments * presence of bleeding disorders or skin conditions * skin sensitivity issues * history of seizures within the past six months * previous administration of btx-a injection within the last 6 months * presence of * contraindications to dry needling * lack of consent to participate in the study

Keywords: cerebral palsy spasticity dry needling range of motion functional mobility
clinical pharmacological study of gnrh antagonist, cetrorelix for healthy female volunteer

Conditions: Premenopause

Summary: gnrh analogs are globally used for assisted reproduction in infertile patients. to date, in healthy female volunteers the pharmacokinetic and pharmacodynamic profiles of cetrorelix when administered in a single dose have been investigated in studies conducted using doses of 1, 3 and 5 mg. studies performed in premenopausal female volunteers confirmed that cetrorelix rapidly suppresses luteinizing hormone (lh) and estradiol and shows dose-dependent prolongation of the duration of lh suppression. however, there have been few reports of studies of the relationship between the cetrorelix dosage and its effect on lh surge. in the present study, we investigated the effect of cetrorelix on lh surge when this drug was administered in single doses of 1, 2 and 3 mg.

to evaluate that effect on lh surge, we investigated the efficacy of cetrorelix in delaying the start of the lh surge in comparison with the control menstrual cycle when saline was administered, and also examined the mode of disappearance of pulsatile lh secretion during the cetrorelix administration menstrual cycle.

Eligibility criteria:
inclusion criteria: * a bmi of 18 years old and \ 25 * menstrual cycles was within the range of 25\~31 days exclusion criteria: * use of a drug (e.g., oral contraceptives, drugs for treatment of hyperprolactinemia, gnrh agonists, sex steroid hormones, psychoactive drugs, etc.) * serious disease of the endocrine system, liver, kidney, heart, lung, digestive system, etc. * a generalized drug allergy

Keywords: infertility, menstrual cycle, lh surge
web-based adolescent motivational enhancement study

Conditions: Alcohol Risk Behaviors; Health Care Services Quality of Care

Summary: the proposed study is a randomized controlled trial that compares the effectiveness of an electronic personalized health screening app incorporating motivational feedback (i.e. "check yourself") to usual care among moderate to high risk alcohol users. the purpose of this study is to determine whether check yourself is more effective than usual care in reducing alcohol consumption and binge drinking and improving quality of care among adolescents receiving school-based health clinic services.


Eligibility criteria:
inclusion criteria: * eligible individuals will be 13-18 years old who are able to read and comprehend english. * participants who indicate alcohol use consistent with moderate to high risk on the check yourself app. exclusion criteria: individuals will be excluded from the study if: * they do not meet age requirements * do not have a study visit at a participating school-based health clinic * lack the means to complete follow-up interviews (i.e. have neither telephone or internet access) * are not able to read or comprehend english
assessments on current pain managements in upper gastrointestinal cancer patients

Conditions: Pain; Neuropathic Pain; Depression; Quality of Life; Upper GI Cancer

Summary: pain is one of the most common symptoms associated with cancer. the approach to pain management compresses routine pain assessments, utilizes both pharmacologic and nonpharmacologic interventions, and requires ongoing reevaluation of the patient. cancer pain can be well controlled in the vast majority of patients if the algorithms of pain control are systematically applied, carefully monitored, and tailored to the needs of the individual patient.this study is aimed to assess the current pain managements in upper gastrointestinal cancer patients in taiwan. the effects of neuropathic pain and depression on the enrolled patients would also be assessed.


Eligibility criteria:
inclusion criteria: * with a diagnose of advanced upper gi cancer based on pathology or imaging studies * could report pain intensities and answer questionnaires by him/herself exclusion criteria: * with major neurologic or psychiatric diseases * could not report pain intensities and answer questionnaires by him/herself
a study to evaluate 5 μg/kg tbo-filgrastim in infants, children and adolescents with solid tumors without bone marrow involvement

Conditions: Neutropenia

Summary: the purpose of the study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of daily subcutaneous administration of 5 μg/kg tbo-filgrastim in infants, children and adolescents with solid tumors without bone marrow involvement.


Eligibility criteria:
inclusion: 1. male or female infants, children and adolescents aged 1 month to \<16 years. 2. patients with solid tumors without bone marrow involvement, who are scheduled to receive myelosuppressive ctx. 3. body weight ≥5 kg. 4. patients must have an initial diagnosis and histologic proof of their malignancy. all enrolled subjects should have signed consent for a ctx regimen that is known to be myelotoxic, with counts expected to drop below the absolute neutrophil count (anc) of 0.5 × 109/l for at least 3 days. these regimens would include at least one of the following: * etoposide * doxorubicin * ifosfamide * cyclophosphamide 5. anc and platelet count: patients must have an anc \>1 × 109/l and a platelet count \>100 × 109/l to be eligible for therapy at the start of ctx. 6. normal cardiac, renal, and hepatic function. 7. all subjects must have a life expectancy of 12 weeks or more. 8. performance status: lansky performance score \>60 (age 1 to \<16 years). * more criteria may apply, please contact the investigator for more information. exclusion: 1. bone marrow involvement. 2. active myelogenous leukemia or history of myelogenous leukemia. 3. previous treatment with colony-stimulating factors (granulocyte colony-stimulating factor \[g-csf\], granulocyte-macrophage colony-stimulating factor, interleukin 11 \[il-11\]) less than 6 weeks prior to study entry. 4. history of congenital neutropenia or cyclic neutropenia. 5. pregnant or nursing female patients. 6. fertile patients who do not agree to use highly reliable contraceptive measures prior bone marrow or stem cell transplant, or prior radiation to ≥25% of bone marrow within the 4 weeks prior to the first tbo-filgrastim dose. 7. ongoing active infection or history of infectious disease within 2 weeks prior to the screening visit. 8. treatment with lithium at screening or planned during the study * more criteria may apply, please contact the investigator for more information.

Keywords: neutropenia
study of longitudinal observation for patient with x-linked hypophosphatemic rickets/osteomalacia in collaboration with asian partners

Conditions: X-Linked Hypophosphatemia

Summary: through observation of patients with x-linked hypophosphatemic rickets/osteomalacia (xlh) for up to 10 years, the study intends to collect data that allow achievement of the following objectives: 1. to determine medical characteristics of the disease and the disease process 2. to determine physical and psychological burden on patients as well as economic burden 3. to assess the efficacy and safety of the treatment of the disease


Eligibility criteria:
inclusion criteria: * patients must meet at least one of the following: 1. documented phex gene mutation 2. documented phex gene mutation in at least one family member with x-linked genetic relationship 3. documented fgf23 \>30 pg/ml * typical clinical findings of rickets/osteomalacia * written informed consent obtained from patients aged \>=18 years or from parents or legally acceptable representatives of patients aged \<18 years exclusion criteria: * participation in any clinical study (trial) at the time of informed consent * any patient whose participation in the study is considered inappropriate by the investigator or the subinvestigator

Keywords: xlh
study of bms-562086 in the treatment of outpatients with major depressive disorder

Conditions: Major Depressive Disorder

Summary: the purpose of this clinical research study is to learn whether bms-562086 is both safe and effective in treating outpatients with major depressive disorder.


Eligibility criteria:
inclusion criteria: * outpatient women meeting diagnostic and statistical manual of mental disorders manual, fourth edition, text revision (dsm-iv tr) criteria for a single or recurrent, non-psychotic episode of major depressive disorder (296.2x and 296.3x). * patients whose current depressive episode is at least three months in duration at the baseline visit. exclusion criteria: * males * patients with treatment resistance to other antidepressants